Eagle Health Investments LP Sells 21,100 Shares of Illumina, Inc. $ILMN

Eagle Health Investments LP lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 322,261 shares of the life sciences company’s stock after selling 21,100 shares during the quarter. Illumina comprises approximately 8.0% of Eagle Health Investments LP’s holdings, making the stock its 5th largest holding. Eagle Health Investments LP owned 0.21% of Illumina worth $30,605,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. AQR Capital Management LLC increased its holdings in shares of Illumina by 55.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock worth $313,290,000 after purchasing an additional 1,174,295 shares during the period. Edmond DE Rothschild Holding S.A. grew its position in Illumina by 140.1% during the second quarter. Edmond DE Rothschild Holding S.A. now owns 1,428,692 shares of the life sciences company’s stock worth $136,312,000 after buying an additional 833,750 shares in the last quarter. Thrivent Financial for Lutherans increased its stake in Illumina by 1,558.0% during the second quarter. Thrivent Financial for Lutherans now owns 728,755 shares of the life sciences company’s stock valued at $69,528,000 after acquiring an additional 684,802 shares during the period. Pacer Advisors Inc. acquired a new position in Illumina in the 3rd quarter valued at approximately $61,663,000. Finally, Invesco Ltd. lifted its position in shares of Illumina by 48.9% in the 2nd quarter. Invesco Ltd. now owns 1,353,077 shares of the life sciences company’s stock worth $129,097,000 after acquiring an additional 444,543 shares during the period. 89.42% of the stock is owned by institutional investors.

Illumina Trading Down 0.3%

Shares of ILMN stock opened at $116.51 on Wednesday. The company has a market capitalization of $17.81 billion, a P/E ratio of 21.38, a P/E/G ratio of 2.23 and a beta of 1.45. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $155.53. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55. The firm has a 50-day moving average price of $136.77 and a 200 day moving average price of $116.89.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.09. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The company’s revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the business posted $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Transactions at Illumina

In other Illumina news, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the transaction, the insider owned 17,887 shares in the company, valued at approximately $2,434,241.83. The trade was a 1.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.17% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ILMN shares. Robert W. Baird set a $137.00 price objective on Illumina in a research report on Friday, February 6th. Stifel Nicolaus boosted their price target on shares of Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. Evercore set a $150.00 price objective on shares of Illumina in a research note on Friday, February 6th. Piper Sandler decreased their target price on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research report on Monday, February 9th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Illumina has an average rating of “Hold” and a consensus price target of $127.94.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.